Analysis of Clinical Trials on Therapies for Prostate Cancer in Mainland China and Globally from 2010 to 2020

被引:3
|
作者
Chen, Kun [1 ]
Jiang, Kehua [2 ]
Tang, Lannan [2 ]
Chen, Xiaolong [2 ]
Hu, Jianxin [2 ]
Sun, Fa [2 ]
机构
[1] Guizhou Prov Peoples Hosp, NHC Key Lab Pulm Immune Related Dis, Guiyang, Peoples R China
[2] Guizhou Prov Peoples Hosp, Dept Urol, Guiyang, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
drug trials; prostate cancer; chemotherapy; gene-targeted; immunotherapy; IMMUNE-CHECKPOINT INHIBITORS; RADIOTHERAPY; STATISTICS;
D O I
10.3389/fonc.2021.647110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The overall aging of the world population has contributed to the continuous upward trend in the incidence of prostate cancer (PC). Trials on PC therapy have been extensively performed, but no study has analyzed the overall trends and characteristics of these trials, especially for those carried out in China. This study aimed to provide insights on the future direction of drug development in PC, thus supplying essential supportive data for stakeholders, including researchers, patients, investors, clinicians, and pharmaceutical industry. The details of the clinical trials of drug therapies for PC during January 1, 2010, to January 1, 2020, were collected from Pharmaprojects. A total of 463 clinical trials on different therapies with 132 different drugs were completed. The long-acting endocrine therapy with few side effects, radiotherapy combined with immune checkpoint inhibitors, gene-targeted chemotherapeutics, and novel immunotherapeutic products changed the concept of PC treatment. In mainland China, 31 trials with 19 drugs have been completed in the 10 assessment years. China has initiated a few trials investigating a limited number of drug targets, centered in a markedly uneven geographical distribution of leading clinical trial units; hence, the development of PC drugs has a long way to go. Given the large patient pool, China deserves widespread attention for PC drug research and development. These findings might have a significant impact on scientific research and industrial investment.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Progress of attraction websites in Mainland China: From 2005 to 2010
    Zhong, Lina
    Wu, Bihu
    Leung, Daniel
    INFORMATION AND COMMUNICATION TECHNOLOGIES IN TOURISM 2011, 2011, : 89 - +
  • [32] Outcome of prostate cancer with CNS metastasis: An analysis of SEER database (2010-2020)
    Lee, Hyun
    Mei, Lin
    Baralo, Bohdan
    Poklepovic, Andrew Stewart
    Paul, Asit K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] Trends of Phase I Clinical Trials of New Drugs in Mainland China Over the Past 10 Years (2011-2020)
    Chen, Chen
    Lou, Ning
    Zheng, Xin
    Wang, Shasha
    Chen, Haizhu
    Han, Xiaohong
    FRONTIERS IN MEDICINE, 2021, 8
  • [34] A National Cancer Clinical Trials System for Targeted Therapies
    Mendelsohn, John
    SCIENCE TRANSLATIONAL MEDICINE, 2011, 3 (75)
  • [35] GLOBAL DISTRIBUTION OF CLINICAL TRIALS FOR TARGETED CANCER THERAPIES
    Zhao, A.
    Li, M.
    VALUE IN HEALTH, 2020, 23 : S56 - S56
  • [36] Genetically directed therapies for cancer in early clinical trials
    McNamee, D
    LANCET, 1997, 349 (9065): : 1605 - 1605
  • [37] Looking towards personalized clinical trials for cancer therapies
    Baryan, Hardaman
    PHARMACOGENOMICS, 2012, 13 (13) : 1441 - 1442
  • [38] Discussion - Clinical trials and combination therapies in lung cancer
    Dr. Lynch
    Dr. Govindan
    Dr. Shepherd
    Dr. Janne
    Dr. Sorensen
    Dr. Heymach
    Dr. Natale
    Dr. Lilenbaum
    Dr. Hanke
    Dr. Engelman
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S176 - S176
  • [39] An update on clinical trials of targeted therapies in thyroid cancer
    Haraldsdottir, Sigurdis
    Shah, Manisha H.
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (01) : 36 - 44
  • [40] Breast-cancer therapies start clinical trials
    Gordon, S
    LANCET, 1996, 347 (9018): : 1823 - 1823